CPhI survey: pharma leaders optimistic about the future According to a recent survey of executives conducted by CPhI, COVID-19’s impact is driving manufacturing and CDMOs are fueling industry growth.
CPhI has released a survey taking the post-pandemic temperature pharmaceutical leaders, gauging how they feel about the industry’s prospects in the immediate and medium-term future. The findings in the report (to be outlined in a May 20 session during the organization’s virtual CPhI Discover event) reveal companies and governmental bodies alike are keenly interested in increasing regional self-reliance, reducing system complexity, and more.
Outsourcing-Pharma spoke about the survey, and notable CPhI Discover sessions worth a closer look, with Tara Dougal, head of content at Informa Markets.
The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
The CD19-targeted antibody drug conjugate (ADC) was granted accelerated approval by the US regulator based on overall response rate.
The approval also covers patients with DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
“This is the first ever approval of a PBD based ADC,” noted Chris Martin, CEO, ADC Therapeutics, on a conference call about the regulatory development and commercial launch.
The Lausanne, Switzerland based biotech is now entering
European Commission to take legal action against AstraZeneca over COVID-19 vaccine supplies The European Commission has decided to bring legal proceedings against AstraZeneca, it confirmed today. But AstraZeneca says the litigation is without merit, adding it will ‘strongly defend itself’ in court.
The European Commission accuses AstraZeneca of a breach of contract over COVID-19 vaccine deliveries.
The announcement follows months of spats as Europe seeks to protect its vaccine supplies: such as Best reasonable efforts
AstraZeneca was due to deliver 180 million vaccines doses to the EU in Q2 2021, totalling 300 million from December to June. However, AstraZeneca now plans to deliver one-third of that by the end of June, of which about 70 million would be in the second quarter, according to reporting from Reuters.
Bristol Myers Squibb to build new cell therapy manufacturing site in the Netherlands Bristol Myers Squibb (BMS) will build a new cell therapy manufacturing site in Leiden, the Netherlands: marking the company’s first cell therapy manufacturing facility in Europe and its fifth globally.
BMS is building up its cell manufacturing footprint and network across the globe. The American pharmaceutical company currently has cell therapy manufacturing facilities in the US: including in Bothwell, WA and Summit, NJ. Last month BMS announced the addition of a new facility in Devens, MA; which has been followed by today’s announcement of the Leiden facility.
Israel has set up COVID-19 vaccine orders with Pfizer and Moderna this week: marking deals over the longer term for the two companies.
The Moderna deal is the company’s first firm agreement for 2022: and the deal includes the option for Israel to purchase the company’s
Meanwhile, Pfizer will also supply Israel with doses in 2022: while elsewhere the company is also in negotiations with the EU for a
Extending Israel s success story into 2022
With 55% of the population already fully vaccinated, Israel is a leader in COVID-19 vaccination and increasingly presented as a model of a successful vaccination campaign for the rest of the world.